vs
Side-by-side financial comparison of Finwise Bancorp (FINW) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $42.7M, roughly 2.0× Finwise Bancorp). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 47.0%).
Finwise Bancorp is a U.S.-based financial holding company that operates primarily through its community banking subsidiary. It offers a full suite of retail and commercial financial services, including deposit accounts, personal loans, mortgage products, small business financing, and wealth management solutions, serving local retail consumers and small to medium-sized business clients across its regional operating markets.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FINW vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $42.7M | $86.8M |
| Net Profit | $2.7M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 6.4% | — |
| Revenue YoY | — | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $42.7M | — | ||
| Q4 25 | $46.9M | $86.8M | ||
| Q3 25 | $36.7M | $67.5M | ||
| Q2 25 | $25.1M | $60.0M | ||
| Q1 25 | $22.1M | $49.3M | ||
| Q4 24 | $21.1M | $73.7M | ||
| Q3 24 | $20.8M | $58.6M | ||
| Q2 24 | $19.8M | $31.1M |
| Q1 26 | $2.7M | — | ||
| Q4 25 | $3.9M | — | ||
| Q3 25 | $4.9M | $-91.3M | ||
| Q2 25 | $4.1M | $-111.7M | ||
| Q1 25 | $3.2M | $-116.2M | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.5M | $-83.5M | ||
| Q2 24 | $3.2M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | 11.7% | -84.7% | ||
| Q3 25 | 17.5% | -140.7% | ||
| Q2 25 | 21.7% | -189.8% | ||
| Q1 25 | 20.1% | -245.8% | ||
| Q4 24 | 17.5% | -117.5% | ||
| Q3 24 | 22.2% | -152.1% | ||
| Q2 24 | 21.1% | -327.6% |
| Q1 26 | 6.4% | — | ||
| Q4 25 | 8.4% | — | ||
| Q3 25 | 13.3% | -135.3% | ||
| Q2 25 | 16.3% | -186.2% | ||
| Q1 25 | 14.4% | -235.5% | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 16.6% | -142.7% | ||
| Q2 24 | 16.1% | -312.2% |
| Q1 26 | $0.20 | — | ||
| Q4 25 | $0.27 | — | ||
| Q3 25 | $0.34 | — | ||
| Q2 25 | $0.29 | $-0.33 | ||
| Q1 25 | $0.23 | $-0.36 | ||
| Q4 24 | $0.19 | $-0.24 | ||
| Q3 24 | $0.25 | $-0.28 | ||
| Q2 24 | $0.24 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $196.6M | $698.6M |
| Total Assets | $899.4M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $163.4M | $297.0M | ||
| Q3 25 | $105.6M | $300.8M | ||
| Q2 25 | $90.1M | $301.2M | ||
| Q1 25 | $120.3M | $359.7M | ||
| Q4 24 | $109.2M | $323.8M | ||
| Q3 24 | $85.8M | $397.5M | ||
| Q2 24 | $89.0M | $412.5M |
| Q1 26 | $196.6M | — | ||
| Q4 25 | $193.2M | $698.6M | ||
| Q3 25 | $187.8M | $702.3M | ||
| Q2 25 | $182.0M | $698.5M | ||
| Q1 25 | $177.4M | $767.9M | ||
| Q4 24 | $173.7M | $710.4M | ||
| Q3 24 | $170.4M | $773.5M | ||
| Q2 24 | $165.8M | $768.5M |
| Q1 26 | $899.4M | — | ||
| Q4 25 | $977.1M | $913.2M | ||
| Q3 25 | $899.9M | $904.9M | ||
| Q2 25 | $842.5M | $907.4M | ||
| Q1 25 | $804.1M | $966.7M | ||
| Q4 24 | $746.0M | $910.4M | ||
| Q3 24 | $683.0M | $991.1M | ||
| Q2 24 | $617.8M | $964.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-28.4M | $-52.6M | ||
| Q3 25 | $3.5M | $-78.7M | ||
| Q2 25 | $-18.3M | $-67.4M | ||
| Q1 25 | $-21.6M | $-103.7M | ||
| Q4 24 | $-15.0M | $-73.3M | ||
| Q3 24 | $-9.8M | $-59.0M | ||
| Q2 24 | $-7.6M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-61.9M | ||
| Q3 25 | $3.4M | $-89.5M | ||
| Q2 25 | $-19.8M | $-74.9M | ||
| Q1 25 | $-23.3M | $-109.9M | ||
| Q4 24 | $-16.1M | $-77.5M | ||
| Q3 24 | $-13.4M | $-61.3M | ||
| Q2 24 | $-7.7M | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | -61.1% | -71.3% | ||
| Q3 25 | 9.4% | -132.7% | ||
| Q2 25 | -79.0% | -124.9% | ||
| Q1 25 | -105.3% | -222.8% | ||
| Q4 24 | -76.0% | -105.1% | ||
| Q3 24 | -64.3% | -104.6% | ||
| Q2 24 | -38.7% | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 10.7% | ||
| Q3 25 | 0.1% | 16.1% | ||
| Q2 25 | 5.8% | 12.4% | ||
| Q1 25 | 7.4% | 12.6% | ||
| Q4 24 | 5.1% | 5.7% | ||
| Q3 24 | 17.2% | 3.9% | ||
| Q2 24 | 0.3% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | -7.26× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | -4.48× | — | ||
| Q1 25 | -6.78× | — | ||
| Q4 24 | -5.37× | — | ||
| Q3 24 | -2.84× | — | ||
| Q2 24 | -2.39× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FINW
| Net Interest Income | $28.1M | 66% |
| Noninterest Income | $14.6M | 34% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
